(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.39%) $79.57
(0.39%) $2.31
(0.55%) $2 353.10
(0.74%) $28.58
(0.85%) $993.00
(-0.31%) $0.927
(-0.37%) $10.85
(-0.23%) $0.798
(0.88%) $92.55
5 days till quarter result
(bmo 2024-05-14)
Expected move: +/- 5.93%
Live Chart Being Loaded With Signals
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy...
Stats | |
---|---|
Šios dienos apimtis | 928 619 |
Vidutinė apimtis | 752 134 |
Rinkos kapitalizacija | 1.47B |
EPS | $0 ( 2024-05-08 ) |
Kita pelno data | ( $-0.970 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.89 |
ATR14 | $0.0360 (0.22%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Jarrett Jennifer | Sell | 11 551 | Common Stock |
2024-03-18 | Jarrett Jennifer | Sell | 12 153 | Common Stock |
2024-03-18 | Jarrett Jennifer | Sell | 1 296 | Common Stock |
2024-02-26 | Jarrett Jennifer | Sell | 24 555 | Common Stock |
2024-02-27 | Jarrett Jennifer | Sell | 34 070 | Common Stock |
INSIDER POWER |
---|
95.54 |
Last 100 transactions |
Buy: 19 279 293 | Sell: 529 920 |
Tūris Koreliacija
Arcus Biosciences Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
MCS | 0.861 |
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Arcus Biosciences Inc Koreliacija - Valiuta/Žaliavos
Arcus Biosciences Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $117.00M |
Bruto pelnas: | $101.00M (86.32 %) |
EPS: | $-4.15 |
FY | 2023 |
Pajamos: | $117.00M |
Bruto pelnas: | $101.00M (86.32 %) |
EPS: | $-4.15 |
FY | 2022 |
Pajamos: | $112.00M |
Bruto pelnas: | $98.00M (87.50 %) |
EPS: | $-3.71 |
FY | 2021 |
Pajamos: | $382.88M |
Bruto pelnas: | $382.88M (100.00 %) |
EPS: | $0.964 |
Financial Reports:
No articles found.
Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.